Arazy Group Consultants Inc.

Home
Arazy Group Consultants Inc.

Call Website Contact the practice

Our expertise is regulatory affairs and quality assurance for the medical device industry, culminatin Arazy Group Consultants Inc.

is a global, multifaceted regulatory affairs firm that provides all types of medical device manufacturers with innovative, client-specific solutions throughout the product life cycle – from early development to post-market activities. Arazy Group is constantly pursuing advanced solutions for the medical device industry and seeks to align its clients with the global economy and the ever-changing regulatory landscape. Please visit www.arazygroup.com or www.licensale.com for more information. Follow us on Twitter: https://twitter.com/arazygroup
Follow us on LinkedIn: http://www.linkedin.com/company/arazy-group

29/06/2026

Malaysia just made a major regulatory move for the aesthetic device industry.
With the new Medical Device (Designated Medical Device) Order 2026, aesthetic technologies are officially entering Malaysia’s medical device framework.

Why this matters:
-Laser technologies are now formally regulated medical devices
-HIFU devices officially fall under medical device oversight
-Liposuction technologies now require regulatory compliance
-Aesthetic claims and intended use are becoming a major regulatory focus
-Technical documentation and labeling expectations are increasing

The regulation specifically includes:
-Alexandrite, Diode, Erbium YAG, Fractional CO₂, Nd, Pulse-Dye, and Ruby lasers
-HIFU systems
-Liposuction devices

One of the biggest shifts:
The line between aesthetic technology and regulated medical devices is disappearing globally.

Malaysia is joining the growing regulatory trend toward stricter oversight of:
-energy-based devices
-body contouring technologies
-non-invasive aesthetic platforms
-medical aesthetic solutions

For manufacturers, this means reassessing:
-product classification
-intended use claims
-labeling
-market access strategy

At Arazy Group, we help MedTech and aesthetic device companies navigate evolving global regulations and accelerate compliant market access worldwide.

Watch the full update: https://hubs.ly/Q04mZlNZ0
More insights: https://hubs.ly/Q04mZgRb0

25/06/2026

June 2026 RegTalk Key Takeaways: Global Regulatory Changes Are Accelerating Faster Than Ever.

The MedTech industry is entering a new phase where:
-AI-enabled technologies are expanding rapidly
-Reliance pathways are reshaping approvals
-Digital compliance expectations are becoming stricter worldwide

But regulators are no longer evaluating only the device.
They’re evaluating the entire compliance ecosystem:
-UDI
-Cybersecurity
-Electronic labeling
-Post-market surveillance
-AI transparency
-Global traceability

And globally, the shift is happening fast:
- Malaysia launched faster reliance pathways with Thailand and Singapore
- Vietnam introduced stricter advertising controls
- Egypt simplified registration requirements
- Canada increased scrutiny on device changes and safety claims
- Turkey officially transitioned to mandatory UDI
- Mexico introduced major new labeling requirements

The companies that will scale globally in 2026 won’t just innovate faster.
They’ll build regulatory readiness from day one.

What do you think will become the biggest challenge for MedTech companies over the next 2 years?
Missed the session? Watch it here: https://hubs.ly/Q04mGHDw0

24/06/2026

The IMDRF just signaled a major shift for AI-enabled medical devices:
Regulation will no longer focus only on approval…
but on the entire AI life cycle.

On 7 April 2026, the IMDRF released a draft Technical Framework for Artificial Intelligence Life Cycle Management, introducing a globally harmonized approach for the development, deployment, monitoring, and maintenance of AI medical devices.

The message is clear:
AI systems in healthcare must be continuously managed, monitored, and evaluated throughout their real-world use.

The framework places strong focus on:
-Data bias and model drift
-Human oversight
-Cybersecurity
-Transparency and explainability
-Adaptive AI and Generative AI systems
-Post-market monitoring

This is more than a guidance update.
It’s a global shift in how regulators are approaching AI in healthcare.

For MedTech and Regulatory teams:
AI governance can no longer start at submission.
It must start from day one of development.

Need support navigating global AI regulatory changes in MedTech? Let’s connect: https://hubs.ly/Q04mx4890

Stay updated with the latest regulatory insights in medical devices and AI governance: https://hubs.ly/Q04mw7tB0

Source: https://hubs.ly/Q04mxftJ0

22/06/2026

Tomorrow.
That’s how fast global regulatory changes are moving.
One country updates a requirement.

One authority accelerates approvals.
And suddenly your launch timeline starts slipping.
That’s the reality of global regulatory strategy in 2026.
Regulatory teams are no longer managing ONE market.

They’re trying to keep up with multiple countries evolving at completely different speeds:
- Malaysia
- Vietnam
- Egypt
- Canada
- Turkey
- Mexico

The biggest challenge today isn’t the regulation itself.
It’s staying ahead before delays become expensive.
While some teams are still discussing next steps…
Others have already submitted.

Tomorrow, we’re breaking down the regulatory changes happening RIGHT NOW across these markets, and what they actually mean for timelines, submissions, and risk exposure.

In 45 minutes, we’ll cover:
- Changes impacting approvals & timelines
- Markets becoming harder to predict
- What regulatory teams should prepare for now
- Practical insights; not generic updates

📅 June 23, 2026 🕗 8:00 AM PST
🔴 Free & Live (recording available)
REGISTER HERE: https://hubs.ly/Q04mb_W20

Question for regulatory teams:
Which market has become the most unpredictable lately? 👇

19/06/2026

Everyone wants faster approvals.
But speed doesn't come from the submission.

It comes from what happens before it.

Most delays are created by:
- Poor structure
- Missing documentation
- Lack of early alignment

Fix that...
And everything moves faster.

Speed isn't something you chase at the finish line.
It's something you build from the start.

Where do YOU think most delays actually come from? 👇

18/06/2026

What happens when Malaysia changes a requirement... and your team in Canada finds out three weeks too late?

That's exactly what's breaking launch timelines right now.

Global regulatory strategy isn't about managing one market anymore.

It's about syncing six countries moving at completely different speeds:
- Malaysia adjusting registration requirements
- Vietnam accelerating its approval processes
- Egypt updating its regulatory framework
- Canada shifting review timelines
- Turkey tightening compliance controls
- Mexico changing market access criteria

The challenge isn't the regulation itself. It's the constant pressure of staying ahead before delays become expensive.

Most teams find out too late. By the time internal discussions start, another company has already submitted.

On June 23, 8:00 AM PST, we're breaking down the regulatory changes happening RIGHT NOW across Malaysia, Vietnam, Egypt, Canada, Turkey, and Mexico.

In 45 minutes, you'll get:
- Changes impacting timelines
- Markets becoming higher risk
- What regulatory teams should prepare for now
- Practical insights, not generic updates

Free, live, and recorded for anyone who can't make it in person.
👉 https://hubs.ly/Q04lWns50

Which of these six markets has become the most unpredictable for your team lately?

17/06/2026

India Regulatory Update: CDSCO Draft Guidance on IVD Imports (2026)

On 30 January 2026, the Central Drugs Standard Control Organization (CDSCO) released a draft guidance for the import of In-Vitro Diagnostic (IVD) medical devices in India.

This update is aimed at improving consistency, completeness, and efficiency in import licence submissions through the CDSCO portal and the National Single Window System (NSWS).

What’s changing?
The guidance clarifies expectations for:
- Import licences (fresh, test, endorsements, subsequent applications)
- Device Master Files (DMF) & Site Master Files (SMF)
- Performance evaluation & stability data
- QMS requirements (ISO 13485)
- Free Sale Certificates & post-market surveillance
- Common deficiencies observed during review

Why this matters
This is a clear shift toward:
- More standardized submissions
- Higher quality technical documentation
- Reduced variability in regulatory review
- Stronger digital regulatory processes in India

Key takeaway: India is not just regulating more; it is standardizing how you enter the market.

Is your team already aligning documentation for India, or still adapting per submission?

Subscribe for updates: https://hubs.ly/Q04lJLvm0
Official details: https://hubs.ly/Q04lKgLL0

10/06/2026

Ecuador Regulatory Update: AI-powered medical devices officially enter the regulatory framework

Ecuador is modernizing its MedTech regulatory system, and the message is clear:
Software is now a regulated medical device.

ARCSA’s new 2026 Technical Regulation replaces the previous 2016 framework and introduces a much more globally aligned approach to medical device oversight.

Why this matters for MedTech companies:
-Ecuador formally recognizes Software as a Medical Device (SaMD)
-AI and Machine Learning Medical Devices (MLMD) now fall within regulatory scope
-The regulation adopts reliance principles through IMDRF-recognized authorities
-Simplified registration pathways may accelerate market access
-ISO 13485 and stronger quality system expectations become central
-Post-market surveillance and technovigilance requirements are reinforced

One of the biggest shifts:
Ecuador is aligning itself with global regulatory trends already seen across major markets.
This is no longer just about hardware devices.

Digital health, AI-enabled technologies, standalone software, and connected medical solutions are now part of the regulatory conversation in LATAM.

Another key point:
The simplified registration pathway allows companies to leverage approvals from high-surveillance regulatory authorities that are part of the IMDRF Management Committee.
This could significantly reduce regulatory complexity for globally approved products entering Ecuador.

Why this matters:

LATAM regulators are rapidly modernizing their frameworks to address:
-AI in healthcare
-digital therapeutics
-software-driven diagnostics
-global regulatory harmonization
-post-market traceability

For MedTech manufacturers, regulatory strategy in Latin America is becoming increasingly interconnected with global compliance models.

At Arazy Group, we help MedTech companies navigate evolving global regulations and accelerate compliant market access worldwide.

Watch the full update: https://hubs.ly/Q04kMW2W0
More insights: https://hubs.ly/Q04kQvmF0

08/06/2026

South Africa is raising the bar for clinical evidence in medical devices.
On September 8, 2025, SAHPRA released its new Guideline on Clinical Evaluation of Medical Devices; and the message is clear:

Clinical evidence is no longer just a premarket requirement.
It’s now a lifecycle expectation.

Key signals from the new guidance:
- Stronger expectations for Clinical Evaluation Reports (CERs)
- Greater focus on real-world clinical evidence
- Integration of post-market surveillance into clinical evaluation
- Specific considerations for Software as a Medical Device (SaMD)
- Closer alignment between clinical evidence and risk management

Why this matters:
This is part of a broader global regulatory shift already happening across the EU, FDA, UK, and other mature markets:
- More data-driven oversight
- More lifecycle monitoring
- More scrutiny on clinical performance after market entry
- Greater expectations for SaMD and digital health products

For manufacturers, clinical evaluation is becoming a continuous regulatory function, not just a submission document.

Manufacturers should now:
- Reassess CER strategies
- Strengthen post-market evidence collection
- Align PMS, risk, and clinical activities
- Prepare for increased scrutiny on SaMD evidence generation

South Africa’s latest update reinforces a global MedTech trend: regulators increasingly expect continuous, real-world, lifecycle clinical evidence.

Subscribe for updates: https://hubs.ly/Q04kw8BZ0
Official details: https://hubs.ly/Q04kvX830

04/06/2026

Two AI agents wrote a regulatory intelligence report.
The third reader - me - only hit "send" after watching them disagree.

That's the methodology behind RegTalk, our Monthly MedTech Regulatory Digest covering ~110 primary sources across the EU, US, UK, Canada, Mexico, China, Japan, Korea, Australia, ASEAN, the GCC, and IMDRF / WHO / MDSAP. Items are scope-filtered to medical devices, IVDs, SaMD, and drug-device combinations, then tiered as CRITICAL, STRATEGIC / MONITOR.

The interesting part isn't how it's generated. It's how it's validated:
-Draft from Agent A
-Independent review by Agent B (different model, different prompt) - scope, tier logic, dates and numbers cross-verified against primary regulator URLs
-Findings adjudicated; v2 produced
-Second-pass review on v2
-Human gate before anything reaches a mailing list

May's cycle caught a Mexican standard misdated by a week, an EU AI Act applicability date that conflated two annexes, and a template bug that leaked "This Week's" into a monthly file.

Not perfect. That's the title. But not bad either.

1. The May report
Download the full RegTalk May digest and breakdown here: https://hubs.ly/Q04kc_Ds0

2. The registration
Get monthly updates and future digests here: https://hubs.ly/Q04kcRK80

3. The deep dive
If you want the full context behind this methodology, read the blog here: https://hubs.ly/Q04kcMD10

What did the AIs miss? Tell me.

Address

West Georgia, Vancouver BC

V6H 3R9

Opening Hours

Monday	09:00 - 17:00
Tuesday	09:00 - 17:00
Wednesday	09:00 - 17:00
Thursday	09:00 - 17:00
Friday	09:00 - 17:00

Telephone

+16046816888

Website

http://arazygroup.com/

Alerts

Be the first to know and let us send you an email when Arazy Group Consultants Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Arazy Group Consultants Inc.:

Want your practice to be the top-listed clinic?

Country:

City: